Tislelizumab First-Line (1L) Gastric/gastroesophageal Junction Cancer (G/GEJ) Treatment Efficacy on Patient-Reported Outcome (Pro)-Based Symptom Endpoints Adjusting for Informative Missing Data Bias: Results from RATIONALE 305.